Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 279

1.

Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.

Tissandié E, Morelle W, Berthelot L, Vrtovsnik F, Daugas E, Walker F, Lebrec D, Trawalé JM, Francoz C, Durand F, Moura IC, Paradis V, Moreau R, Monteiro RC.

Kidney Int. 2011 Dec;80(12):1352-63. doi: 10.1038/ki.2011.276. Epub 2011 Aug 24.

2.

Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.

Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Dramé M, Toupance O, Rieu P, Monteiro RC, Touré F.

Kidney Int. 2015 Oct;88(4):815-22. doi: 10.1038/ki.2015.158. Epub 2015 Jun 10.

PMID:
26061544
3.

Sugars and alcohol: IgA-associated renal diseases in alcoholic cirrhosis.

Novak J, Julian BA.

Kidney Int. 2011 Dec;80(12):1252-4. doi: 10.1038/ki.2011.302.

4.

The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.

Tamouza H, Chemouny JM, Raskova Kafkova L, Berthelot L, Flamant M, Demion M, Mesnard L, Paubelle E, Walker F, Julian BA, Tissandié E, Tiwari MK, Camara NO, Vrtovsnik F, Benhamou M, Novak J, Monteiro RC, Moura IC.

Kidney Int. 2012 Dec;82(12):1284-96. doi: 10.1038/ki.2012.192. Epub 2012 Sep 5.

5.

Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction.

Papista C, Lechner S, Ben Mkaddem S, LeStang MB, Abbad L, Bex-Coudrat J, Pillebout E, Chemouny JM, Jablonski M, Flamant M, Daugas E, Vrtovsnik F, Yiangou M, Berthelot L, Monteiro RC.

Kidney Int. 2015 Aug;88(2):276-85. doi: 10.1038/ki.2015.94. Epub 2015 Mar 25.

PMID:
25807036
6.

Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy.

Satake K, Shimizu Y, Sasaki Y, Yanagawa H, Suzuki H, Suzuki Y, Horikoshi S, Honda S, Shibuya K, Shibuya A, Tomino Y.

BMC Nephrol. 2014 Jun 13;15:89. doi: 10.1186/1471-2369-15-89.

7.

Role of IgA receptors in the pathogenesis of IgA nephropathy.

Lechner SM, Papista C, Chemouny JM, Berthelot L, Monteiro RC.

J Nephrol. 2016 Feb;29(1):5-11. doi: 10.1007/s40620-015-0246-5. Epub 2015 Nov 14. Review.

PMID:
26572664
8.

Critical Role of Kupffer Cell CD89 Expression in Experimental IgA Nephropathy.

Xu L, Li B, Huang M, Xie K, Li D, Li Y, Gu H, Fang J.

PLoS One. 2016 Jul 20;11(7):e0159426. doi: 10.1371/journal.pone.0159426. eCollection 2016.

9.

New insights in the pathogenesis of IgA nephropathy.

Monteiro RC.

Nefrologia. 2005;25 Suppl 2:82-6.

10.

Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors.

Roccatello D, Picciotto G, Torchio M, Ropolo R, Ferro M, Franceschini R, Quattrocchio G, Cacace G, Coppo R, Sena LM, et al.

Lab Invest. 1993 Dec;69(6):714-23.

PMID:
8264233
11.

Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy.

van der Boog PJ, De Fijter JW, Van Kooten C, Van Der Holst R, Van Seggelen A, Van Es LA, Daha MR.

Kidney Int. 2003 Feb;63(2):514-21.

12.
13.

Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1.

Ebefors K, Liu P, Lassén E, Elvin J, Candemark E, Levan K, Haraldsson B, Nyström J.

BMC Nephrol. 2016 Apr 5;17:40. doi: 10.1186/s12882-016-0251-5.

14.

Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA.

Grossetête B, Launay P, Lehuen A, Jungers P, Bach JF, Monteiro RC.

Kidney Int. 1998 May;53(5):1321-35.

15.

The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy.

Schmitt R, Ståhl AL, Olin AI, Kristoffersson AC, Rebetz J, Novak J, Lindahl G, Karpman D.

J Immunol. 2014 Jul 1;193(1):317-26. doi: 10.4049/jimmunol.1302249. Epub 2014 May 21.

16.

Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.

Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J.

J Clin Invest. 2009 Jun;119(6):1668-77. doi: 10.1172/JCI38468. Epub 2009 May 26.

17.

Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy.

Kim MJ, Schaub S, Molyneux K, Koller MT, Stampf S, Barratt J.

PLoS One. 2016 Dec 8;11(12):e0166830. doi: 10.1371/journal.pone.0166830. eCollection 2016.

18.

IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells.

Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, Julian BA, Wyatt RJ, Mestecky J.

Kidney Int. 2005 Feb;67(2):504-13.

19.

Association of IgG co-deposition with serum levels of galactose-deficient IgA1 in pediatric IgA nephropathy.

Eison TM, Hastings MC, Moldoveanu Z, Sanders JT, Gaber L, Walker PD, Lau KK, Julian BA, Novak J, Wyatt RJ.

Clin Nephrol. 2012 Dec;78(6):465-9. doi: 10.5414/CN107423.

20.

Molecular Insights into the Pathogenesis of IgA Nephropathy.

Robert T, Berthelot L, Cambier A, Rondeau E, Monteiro RC.

Trends Mol Med. 2015 Dec;21(12):762-75. doi: 10.1016/j.molmed.2015.10.003. Epub 2015 Nov 21. Review.

PMID:
26614735

Supplemental Content

Support Center